Literature DB >> 3500531

'Immune complex' mediated intravascular hemolysis due to IgM cephalosporin-dependent antibody.

A Salama1, B Göttsche, T Schleiffer, C Mueller-Eckhardt.   

Abstract

Immune hemolytic anemia (IHA) related to cephalosporins is rare and generally considered to be the result of a drug-adsorption mechanism. In previously reported cases, the hemolysis was usually extravascular and the causative antibodies were IgG, incapable of activating complement, and demonstrable by the direct or indirect antiglobulin test using red cells (RBCs) pretreated in vitro with cephalosporin. The authors report a patient in whom acute intravascular hemolysis developed while she was receiving cefotaxime (a cephalosporin as yet not reported to cause IHA). The patient's RBCs were coated only with complement fragments (C3d), even at the peak of the hemolytic episode. Her serum and eluates repeatedly yielded negative results when tested against normal or cephalosporin-coated RBCs. However, strong hemagglutination and C5b-9-mediated hemolysis were observed if the patient's serum was tested against RBCs in the presence of the drug, its ex vivo antigen and, to a lesser degree, cephalothin and ceftriaxon, but not in the presence of penicillin and other related cephalosporins. The positive reactions were not changed by preincubating the serum with different amounts of the drugs. All of these findings reflect the typical picture of drug-induced IHA by the so-called "immune complex" mechanism and not by the drug-adsorption mechanism. The authors conclude that cephalosporin can cause immune hemolysis in two ways: the drug-adsorption mechanism and, as described here, the "immune complex" mechanism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500531     DOI: 10.1046/j.1537-2995.1987.27688071694.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 3.  Adverse effects of newer cephalosporins. An update.

Authors:  J W Thompson; R F Jacobs
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

4.  When a transfusion in an emergency service is not really urgent: hyperhaemolysis syndrome in a child with sickle cell disease.

Authors:  Sara Chinchilla Langeber; Marta Pilar Osuna Marco; María Benedit; Áurea Cervera Bravo
Journal:  BMJ Case Rep       Date:  2018-03-27

5.  Autoimmune Hemolytic Anemia - Fascinating from a Laboratory as well as from a Clinical Point of View.

Authors:  Hans-Gert Heuft; Axel Pruß
Journal:  Transfus Med Hemother       Date:  2015-09-27       Impact factor: 3.747

6.  Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption.

Authors:  Yuanjun Wu; Yong Wu; Yong Yang; Baochan Chen; Jianqun Li; Ganping Guo; Fu Xiong
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.